Conference Coverage

Here’s how to tackle teenage tanning


 

EXPERT ANALYSIS FROM THE SPD ANNUAL MEETING

References

Moving to the legislative and policy level, change can be achieved when stakeholders band together to “ban the tan,” said Dr. Smith. “The best way to do it is with a village. It really takes a lot of people to do this.”

There are solid epidemiologic and economic reasons to focus on the skin cancer epidemic, said Dr. Smith. Skin cancer is now the most common cancer in the United States, and more new cases “are diagnosed each year than breast, prostate, lung, and colon cancers combined,” she said. Of nonmelanoma skin cancers, 90% are thought to be UV-related, and “the vast majority of mutations found in melanoma are caused by UV radiation.”

Skin cancers cost the United States over $8 billion annually, and although promising new immunotherapies are extending the lives of those with melanoma, these treatments cost hundreds of thousands of dollars a year. “This type of treatment is unaffordable for our system,” said Dr. Smith.

Progress is being made, she said, despite industry opposition. Individual states have regulated or banned tanning for minors, and at the federal level, tanning beds are now considered by the FDA to be Class II (moderate-risk) medical devices, a step up from their previous classification as the lowest-risk Class I devices, “The same as a tongue blade,” she said.

Dr. Smith had no relevant financial disclosures.

koakes@frontlinemedcom.com

On Twitter @karioakes

Pages

Recommended Reading

SEER data underscore mortality associated with thin melanomas
MDedge Dermatology
Checkpoint-blocking antibodies appear safe, beneficial in elderly melanoma patients
MDedge Dermatology
T-VEC plus ipilimumab safe, effective in advanced melanoma
MDedge Dermatology
Case series describes melanoma-associated leukoderma presenting as atypical vitiligo
MDedge Dermatology
Dual immune checkpoint blockade found durable in melanoma
MDedge Dermatology
Study tracks distant metastatic patterns of Merkel cell carcinoma
MDedge Dermatology
Study tracks distant metastatic patterns of Merkel cell carcinoma
MDedge Dermatology
40% of top-rated sunscreens fall short of AAD guidelines
MDedge Dermatology
Sunscreens May Fail to Meet SPF Claims on Product Labels
MDedge Dermatology
Pembrolizumab-ipilimumab combo is highly active in advanced melanoma
MDedge Dermatology